LinkedIn
WebsiteCompany Overview
Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company founded in 2009 and headquartered in Austin, Texas. The company focuses on developing therapies for patients with cancer and diabetes by delivering disease-fighting genes using its proprietary, non-viral Oncoprex® Nanoparticle Delivery System and adeno-associated virus (AAV) vectors. Genprex’s lead oncology candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in multiple clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and holds FDA Fast Track and Orphan Drug designations. Its diabetes program, GPX-002, aims to convert pancreatic alpha cells into insulin-producing beta-like cells.
| Metric | Value |
|---|---|
| Ticker | GNPX |
| Exchange | NASDAQ |
| Price (2025-10-16) | $0.4665 |
| One-day change | –44.46% |
| Volume | 26,539,859 shares |
| Employees | 11–50 |
| Headquarters | Austin, Texas |
| Industry | Biotechnology |
| Korean name | ì œë„ˆí”„ë ˆìŠ¤ |
Corporate Structure
Genprex operates as a public company with a staff of approximately 11 to 50 employees. Its executive leadership is led by President and CEO Ryan M. Confer, with key functions spanning research and development, intellectual property, and clinical operations. The company collaborates with academic institutions, including the University of Michigan Rogel Cancer Center and the Lung Cancer Study Collaboration with ALK Positive.
Gene therapy by Sangharsh Lohakare
Developments and News
-
June 2025
At the American Diabetes Association’s 85th Scientific Sessions, Genprex collaborators presented preclinical data on GPX-002, indicating potential for non-viral dosing and functional beta-like cell formation. -
August 4, 2025
Genprex issued a stockholder letter detailing accomplishments and milestones for 2025, including the initiation of patient treatments in two lung cancer trials. -
August 14, 2025
The company published its quarterly pipeline update. REQORSA continues in Phase 2/3 studies for NSCLC and SCLC, and preclinical research explores combination therapies and tumor-suppressor genes. GPX-002 has progressed in Type 1 and Type 2 diabetes models. -
September 2, 2025
Management participated in the H.C. Wainwright 27th Annual Global Investment Conference, providing an overview of gene therapy programs and meeting with investors. -
September 16, 2025
The U.S. Securities and Exchange Commission declared Form S-1 effective, registering 25 million shares for resale under a June 11, 2025 purchase agreement with Lincoln Park Capital Fund, LLC. The agreement may provide up to $10.04 million in gross proceeds, supplementing the $2.46 million previously received. -
October 14, 2025
Genprex announced participation in investor and industry conferences, including presentations of research data on REQORSA at the AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics.
Financial and Strategic Analysis
Genprex’s share price closed at $0.4665 on October 16, 2025, reflecting a 44.46% decline alongside unusually high trading volume. The SEC-effective S-1 and the accompanying 424B3 prospectus formalize a capital-raising mechanism with Lincoln Park Capital Fund, allowing up to $10 million in equity financing. These funds are intended to support the advancement of late-stage clinical trials of REQORSA and preclinical development of GPX-002. The strategy aims to mitigate dilution risk by allowing the company to access capital in tranches aligned with development milestones. This equity financing is designed to complement non-dilutive grants and collaborations, helping Genprex manage operational needs without issuing shares at a consolidated price.
Market Position and Industry Context
Genprex operates in the competitive gene therapy sector, addressing unmet needs in oncology and diabetes. Its systemic, non-viral delivery platform distinguishes it from viral-vector approaches, potentially allowing for repeated dosing with reduced immunogenicity. FDA Fast Track designations for both NSCLC and SCLC trials reflect regulatory support, while Orphan Drug status for SCLC may provide protections in the marketplace. Collaborations with academic institutions and strategic partnerships are intended to strengthen Genprex’s access to clinical expertise. The gene therapy sector is a rapidly expanding market projected to exceed $20 billion by 2030, and Genprex aims to establish a presence in lung cancer and metabolic disease indications.
TL;DR
On October 16, 2025, Genprex’s stock was priced at $0.4665, down 44.46% on substantial volume. On September 16, the SEC declared its S-1 effective, facilitating up to $10 million in funding from Lincoln Park Capital Fund. Conference presentations in June and September highlighted preclinical findings for GPX-002 and REQORSA. The company plans to utilize equity financing to support trials for NSCLC and SCLC and advance diabetes research, with targeted milestones and regulatory actions expected in the upcoming quarters.
